Some visual changes demand that you stop, do not inject, and contact your pharmacy or healthcare provider immediately
Plaintiffs allege that Novo Nordisk failed to adequately warn patients and healthcare providers
Market Problems Arising Unlike FDA-approved drugs, compounded medications are not subject to the same rigorous testing for safety, quality, and efficacy
Mistake 4: Not accounting for syringe dead space Standard syringes have a small amount of dead space in the hub and needle where liquid remains after injection
Red flags requiring immediate attention include: Unexplained weight gain while on semaglutide Severe or persistent gastrointestinal symptoms Signs of pancreatitis (severe abdominal pain radiating to the back) Symptoms of gallbladder disease (right upper quadrant pain, fever, jaundice) Signs of dehydration or kidney problems (decreased urination, dizziness) Hypoglycemia symptoms if taking insulin or sulfonylureas Depression or suicidal thoughts Symptoms of thyroid problems (neck mass, difficulty swallowing, persistent hoarseness) Pregnancy or planning pregnancy (semaglutide should be discontinued at least 2 months before a planned pregnancy) These situations require prompt medical evaluation rather than waiting for a routine follow-up appointment
